Download PDF
Klin Monbl Augenheilkd 2022; 239(03): 263-269
DOI: 10.1055/a-1757-9879
Übersicht

Benefits and Shortcomings of Laboratory Model Systems in the Development of Genetic Therapies

Vorteile und Defizite von Labormodellsystemen bei der Entwicklung von Gentherapieverfahren
Kirsten Bucher   *
1   University Eye Hospital, University Hospital Tübingen Clinic of Ophthalmology, Tubingen, Germany
2   Institute for Ophthalmic Research, University Hospital Tübingen Clinic of Ophthalmology, Tubingen, Germany
,
Eduardo Rodriguez-Bocanegra   *
1   University Eye Hospital, University Hospital Tübingen Clinic of Ophthalmology, Tubingen, Germany
,
M. Dominik Fischer
1   University Eye Hospital, University Hospital Tübingen Clinic of Ophthalmology, Tubingen, Germany
2   Institute for Ophthalmic Research, University Hospital Tübingen Clinic of Ophthalmology, Tubingen, Germany
3   Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom of Great Britain and Northern Ireland
4   Department of Clinical Neurosciences, University of Oxford Nuffield Laboratory of Ophthalmology, Oxford, United Kingdom of Great Britain and Northern Ireland
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Gene therapeutic approaches promise treatment or even a cure of diseases that were previously untreatable. Retinal gene therapies tested in clinical trials comprise a wide range of different strategies, including gene supplementation therapies, in vivo gene editing, modulation of splicing mechanisms, or the suppression of gene expression. To guarantee efficient transfer of genetic material into the respective target cells while avoiding major adverse effects, the development of genetic therapies requires appropriate in vitro model systems that allow tests of efficacy and safety of the gene therapeutic approach. In this review, we introduce various in vitro models of different levels of complexity used in the development of genetic therapies and discuss their respective benefits and shortcomings using the example of adeno-associated virus-based retinal gene therapy.

Zusammenfassung

Gentherapeutische Ansätze versprechen die Behandlung oder sogar Heilung von Erkrankungen, die bisher nicht behandelbar waren. Die in klinischen Studien getesteten Gentherapien für die Netzhaut umfassen ein breites Spektrum unterschiedlicher Strategien, darunter Genergänzungstherapien, In-vivo-Gene-Editing, Modulation von Splicing-Mechanismen oder die Unterdrückung der Genexpression. Um einen effizienten Transfer des genetischen Materials in die jeweiligen Zielzellen zu gewährleisten und gleichzeitig schwerwiegende unerwünschte Wirkungen zu vermeiden, erfordert die Entwicklung von Gentherapien geeignete In-vitro-Modellsysteme, mit denen die Wirksamkeit und Sicherheit des gentherapeutischen Ansatzes getestet werden kann. In diesem Übersichtsartikel werden verschiedene In-vitro-Modelle unterschiedlicher Komplexität vorgestellt, die bei der Entwicklung von Gentherapien verwendet werden, und ihre jeweiligen Vor- und Nachteile werden am Beispiel der AAV-basierten Gentherapie der Netzhaut diskutiert.

Key words

gene therapy - retina - in vitro model - AAV

Schlüsselwörter

Gentherapie - Netzhaut - In-vitro-Modell - AAV

* Bucher and Rodriguez-Bocanegra share first authorship.




Publication History

Received: 06 October 2021

Accepted: 31 January 2022

Article published online:
22 March 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Kumar SR, Markusic DM, Biswas M. et al. Clinical development of gene therapy: results and lessons from recent successes. Mol Ther Methods Clin Dev 2016; 3: 16034
    CrossrefPubMedSearch in Google Scholar
  • 2 Russell S, Bennett J, Wellman JA. et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet 2017; 390: 849-860
    CrossrefPubMedSearch in Google Scholar
  • 3 Lee S, Kang IK, Kim JH. et al. Relationship Between Neutralizing Antibodies Against Adeno-Associated Virus in the Vitreous and Serum: Effects on Retinal Gene Therapy. Transl Vis Sci Technol 2019; 8: 14
    CrossrefPubMedSearch in Google Scholar
  • 4 Bucher K, Rodríguez-Bocanegra E, Dauletbekov D. et al. Immune responses to retinal gene therapy using adeno-associated viral vectors – Implications for treatment success and safety. Prog Retin Eye Res 2021; 83: 100915
    CrossrefPubMedSearch in Google Scholar
  • 5 Moreno AM, Fu X, Zhu J. et al. In Situ Gene Therapy via AAV-CRISPR-Cas9-Mediated Targeted Gene Regulation. Mol Ther 2018; 26: 1818-1827
    CrossrefPubMedSearch in Google Scholar
  • 6 Bulcha JT, Wang Y, Ma H. et al. Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther 2021; 6: 1-24
    CrossrefPubMedSearch in Google Scholar
  • 7 Orlans HO, McClements ME, Barnard AR. et al. Mirtron-mediated RNA knockdown/replacement therapy for the treatment of dominant retinitis pigmentosa. Nat Commun 2021; 12: 1-13
    CrossrefPubMedSearch in Google Scholar
  • 8 Lipinski DM, Thake M, MacLaren RE. Clinical applications of retinal gene therapy. Prog Retin Eye Res 2013; 32: 22-47
    CrossrefPubMedSearch in Google Scholar
  • 9 Ronzitti G, Gross DA, Mingozzi F. Human Immune Responses to Adeno-Associated Virus (AAV) Vectors. Front Immunol 2020; 11: 670
    CrossrefPubMedSearch in Google Scholar
  • 10 Trapani I, Colella P, Sommella A. et al. Effective delivery of large genes to the retina by dual AAV vectors. EMBO Mol Med 2014; 6: 194-211
    CrossrefPubMedSearch in Google Scholar
  • 11 Buck TM, Wijnholds J. Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays. Int J Mol Sci 2020; 21: 4197
    CrossrefPubMedSearch in Google Scholar
  • 12 Tustian AD, Bak H. Assessment of quality attributes for adeno-associated viral vectors. Biotechnol Bioeng 2021; 118: 4186-4203
    CrossrefPubMedSearch in Google Scholar
  • 13 Hornung V, Rothenfusser S, Britsch S. et al. Quantitative expression of toll-like receptor 1–10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002; 168: 4531-4537
    CrossrefPubMedSearch in Google Scholar
  • 14 Wiser C, Kim B, Vincent J. et al. Small molecule inhibition of human cGAS reduces total cGAMP output and cytokine expression in cells. Sci Rep 2020; 10: 7604
    CrossrefPubMedSearch in Google Scholar
  • 15 Ran G, Chen X, Xie Y. et al. Site-Directed Mutagenesis Improves the Transduction Efficiency of Capsid Library-Derived Recombinant AAV Vectors. Mol Ther Methods Clin Dev 2020; 17: 545-555
    CrossrefPubMedSearch in Google Scholar
  • 16 Liu Y, Joo KI, Wang P. Endocytic processing of adeno-associated virus type 8 vectors for transduction of target cells. Gene Ther 2013; 20: 308-317
    CrossrefPubMedSearch in Google Scholar
  • 17 Rumachik NG, Malaker SA, Poweleit N. et al. Methods Matter: Standard Production Platforms for Recombinant AAV Produce Chemically and Functionally Distinct Vectors. Mol Ther Methods Clin Dev 2020; 18: 98-118
    CrossrefPubMedSearch in Google Scholar
  • 18 Grimm D, Lee JS, Wang L. et al. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J Virol 2008; 82: 5887-5911
    CrossrefPubMedSearch in Google Scholar
  • 19 Patrício MI, Barnard AR, Cox CI. et al. The Biological Activity of AAV Vectors for Choroideremia Gene Therapy Can Be Measured by In Vitro Prenylation of RAB6A. Mol Ther Methods Clin Dev 2018; 9: 288-295
    CrossrefPubMedSearch in Google Scholar
  • 20 Couto LB, Buchlis G, Farjo R. et al. Potency assay for AAV vector encoding retinal pigment epithelial 65 protein. Invest Ophthalmol Vis Sci 2016; 57: 759
    CrossrefPubMedSearch in Google Scholar
  • 21 Johnson JS, Samulski RJ. Enhancement of adeno-associated virus infection by mobilizing capsids into and out of the nucleolus. J Virol 2009; 83: 2632-2644
    CrossrefPubMedSearch in Google Scholar
  • 22 Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 1998; 72: 1438-1445
    CrossrefPubMedSearch in Google Scholar
  • 23 Pillay S, Meyer NL, Puschnik AS. et al. An essential receptor for adeno-associated virus infection. Nature 2016; 530: 108-112
    CrossrefPubMedSearch in Google Scholar
  • 24 Jaluria P, Betenbaugh M, Konstantopoulos K. et al. Enhancement of cell proliferation in various mammalian cell lines by gene insertion of a cyclin-dependent kinase homolog. BMC Biotechnol 2007; 7: 1-11
    CrossrefPubMedSearch in Google Scholar
  • 25 Russell DW, Miller AD, Alexander IE. Adeno-associated virus vectors preferentially transduce cells in S phase. Proc Natl Acad Sci U S A 1994; 91: 8915-8919
    CrossrefPubMedSearch in Google Scholar
  • 26 Ellis BL, Hirsch ML, Barker JC. et al. A survey of ex vivo/in vitro transduction efficiency of mammalian primary cells and cell lines with Nine natural adeno-associated virus (AAV1–9) and one engineered adeno-associated virus serotype. Virol J 2013; 10: 1-10
    CrossrefPubMedSearch in Google Scholar
  • 27 Gonzalez-Cordero A, Goh D, Kruczek K. et al. Assessment of AAV Vector Tropisms for Mouse and Human Pluripotent Stem Cell–Derived RPE and Photoreceptor Cells. Hum Gene Ther 2018; 29: 1124-1139
    CrossrefPubMedSearch in Google Scholar
  • 28 Achilli C, Ciana A, Minetti G. Immortalized HEK 293 kidney cell lines as models of renal cells: friends or foes?. J Controversies Biomed Res 2018; 4: 6-9
    CrossrefPubMedSearch in Google Scholar
  • 29 Landry JJM, Pyl PT, Rausch T. et al. The genomic and transcriptomic landscape of a HeLa cell line. G3 (Bethesda) 2013; 3: 1213-1224
    CrossrefPubMedSearch in Google Scholar
  • 30 Park EK, Jung HS, Yang HI. et al. Optimized THP-1 differentiation is required for the detection of responses to weak stimuli. Inflamm Res 2007; 56: 45-50
    CrossrefPubMedSearch in Google Scholar
  • 31 Schwende H, Fitzke E, Ambs P. et al. Differences in the state of differentiation of THP-1 cells induced by phorbol ester and 1,25-dihydroxyvitamin D3. J Leukoc Biol 1996; 59: 555-561
    CrossrefPubMedSearch in Google Scholar
  • 32 Li ZH, Si Y, Xu G. et al. High-dose PMA with RANKL and MCSF induces THP-1 cell differentiation into human functional osteoclasts in vitro . Mol Med Rep 2017; 16: 8380-8384
    CrossrefPubMedSearch in Google Scholar
  • 33 Zaiss AK, Cotter MJ, White LR. et al. Complement is an essential component of the immune response to adeno-associated virus vectors. J Virol 2008; 82: 2727-2740
    CrossrefPubMedSearch in Google Scholar
  • 34 Ye Y, Gaugler B, Mohty M. et al. Plasmacytoid dendritic cell biology and its role in immune-mediated diseases. Clin Transl Immunol 2020; 9: e1139
    CrossrefPubMedSearch in Google Scholar
  • 35 Zhu J, Huang X, Yang Y. The TLR9-MyD88 pathway is critical for adaptive immune responses to adenoassociated virus gene therapy vectors in mice. J Clin Invest 2009;
    CrossrefPubMedSearch in Google Scholar
  • 36 Cho CH, Yoon SY, Lee CK. et al. Effect of interleukin-29 on interferon-α secretion by peripheral blood mononuclear cells. Cell J 2015; 16: 528-537
    CrossrefPubMedSearch in Google Scholar
  • 37 Rossi A. Intracellular fate of AAV particles in human Dendritic Cell and impact on Gene Transfer. 2016. Accessed May 5, 2021 at: https://tel.archives-ouvertes.fr/tel-02491137
    PubMed
  • 38 Rossi A, Dupaty L, Aillot L. et al. Vector uncoating limits adeno-associated viral vector-mediated transduction of human dendritic cells and vector immunogenicity. Sci Rep 2019; 9: 1-14
    CrossrefPubMedSearch in Google Scholar
  • 39 Sauter A, Mc Duffie Y, Boehm H. et al. Surface-mediated priming during in vitro generation of monocyte-derived dendritic cells. Scand J Immunol 2015; 81: 56-65
    CrossrefPubMedSearch in Google Scholar
  • 40 Ilchmann A, Krause M, Heilmann M. et al. Impact of culture medium on maturation of bone marrow-derived murine dendritic cells via the aryl hydrocarbon receptor. Mol Immunol 2012; 51: 42-50
    CrossrefPubMedSearch in Google Scholar
  • 41 Liu C, Oikonomopoulos A, Sayed N. et al. Modeling human diseases with induced pluripotent stem cells: from 2D to 3D and beyond. Development 2018; 145: dev156166
    CrossrefPubMedSearch in Google Scholar
  • 42 Kruczek K, Swaroop A. Pluripotent stem cell-derived retinal organoids for disease modeling and development of therapies. Stem Cells 2020; 38: 1206-1215
    CrossrefPubMedSearch in Google Scholar
  • 43 Lingam S, Liu Z, Yang B. et al. cGMP-grade human iPSC-derived retinal photoreceptor precursor cells rescue cone photoreceptor damage in non-human primates. Stem Cell Res Ther 2021; 12: 1-14
    CrossrefPubMedSearch in Google Scholar
  • 44 Jha BS, Bharti K. Regenerating Retinal Pigment Epithelial Cells to Cure Blindness: A Road Towards Personalized Artificial Tissue. Curr Stem Cell Rep 2015; 1: 79-91
    CrossrefPubMedSearch in Google Scholar
  • 45 Kuznetsova AV, Kurinov AM, Aleksandrova MA. Cell models to study regulation of cell transformation in pathologies of retinal pigment epithelium. J Ophthalmol 2014; 2014: 801787
    CrossrefPubMedSearch in Google Scholar
  • 46 Hansen KA, Sugino IK, Yagi F. et al. Adeno-associated virus encoding green fluorescent protein as a label for retinal pigment epithelium. Invest Ophthalmol Vis Sci 2003; 44: 772-780
    CrossrefPubMedSearch in Google Scholar
  • 47 Cereso N, Pequignot MO, Robert L. et al. Proof of concept for AAV2/5-mediated gene therapy in iPSC-derived retinal pigment epithelium of a choroideremia patient. Mol Ther Methods Clin Dev 2014; 1: 14011
    CrossrefPubMedSearch in Google Scholar
  • 48 Auricchio A, Kobinger G, Anand V. et al. Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model. Hum Mol Genet 2001; 10: 3075-3081
    CrossrefPubMedSearch in Google Scholar
  • 49 Garita-Hernandez M, Routet F, Guibbal L. et al. AAV-Mediated Gene Delivery to 3D Retinal Organoids Derived from Human Induced Pluripotent Stem Cells. Int J Mol Sci 2020; 21: 994
    CrossrefPubMedSearch in Google Scholar
  • 50 Wright JF, Sumaroka M. Rab Escort Protein Potency Assay. U.S. Patent 201662418637P, 11.09.2019
    PubMedSearch in Google Scholar
  • 51 Kumar MV, Nagineni CN, Chin MS. et al. Innate immunity in the retina: Toll-like receptor (TLR) signaling in human retinal pigment epithelial cells. J Neuroimmunol 2004; 153: 7-15
    CrossrefPubMedSearch in Google Scholar
  • 52 Nagineni CN, Pardhasaradhi K, Martins MC. et al. Mechanisms of interferon-induced inhibition of Toxoplasma gondii replication in human retinal pigment epithelial cells. Infect Immun 1996; 64: 4188-4196
    CrossrefPubMedSearch in Google Scholar
  • 53 Achberger K, Probst C, Haderspeck JC. et al. Merging organoid and organ-on-a-chip technology to generate complex multi-layer tissue models in a human retina-on-a-chip platform. Elife 2019; 8: e46188
    CrossrefPubMedSearch in Google Scholar
  • 54 Cowan CS, Renner M, De Gennaro M. et al. Cell Types of the Human Retina and Its Organoids at Single-Cell Resolution. Cell 2020; 182: 1623-1640.e34
    CrossrefPubMedSearch in Google Scholar
  • 55 Kruczek K, Qu Z, Gentry J. et al. Gene Therapy of Dominant CRX-Leber Congenital Amaurosis using Patient Stem Cell-Derived Retinal Organoids. Stem Cell Reports 2021; 16: 252-263
    CrossrefPubMedSearch in Google Scholar
  • 56 Quinn PM, Buck TM, Mulder AA. et al. Human iPSC-Derived Retinas Recapitulate the Fetal CRB1 CRB2 Complex Formation and Demonstrate that Photoreceptors and Müller Glia Are Targets of AAV5. Stem Cell Reports 2019; 12: 906-919
    CrossrefPubMedSearch in Google Scholar
  • 57 Achberger K, Cipriano M, Düchs M. et al. Human stem cell-based retina on chip as new translational model for validation of AAV retinal gene therapy vectors. Stem Cell Reports 2021; 16: 2242-2256
    CrossrefPubMedSearch in Google Scholar
  • 58 Singh PK, Kumar A. Retinal photoreceptor expresses toll-like receptors (TLRs) and elicits innate responses following TLR ligand and bacterial challenge. PLoS One 2015; 10: e0119541
    CrossrefPubMedSearch in Google Scholar
  • 59 Sauter MM, Kolb AW, Brandt CR. Toll-like receptors 4, 5, 6 and 7 are constitutively expressed in non-human primate retinal neurons. J Neuroimmunol 2018; 322: 26-35
    CrossrefPubMedSearch in Google Scholar
  • 60 Lin X, Fang D, Zhou H. et al. The expression of Toll-like receptors in murine Müller cells, the glial cells in retina. Neurol Sci 2013; 34: 1339-1346
    CrossrefPubMedSearch in Google Scholar
  • 61 Yin X, Mead BE, Safaee H. et al. Engineering Stem Cell Organoids. Cell Stem Cell 2016; 18: 25-38
    CrossrefPubMedSearch in Google Scholar
  • 62 Zhong X, Gutierrez C, Xue T. et al. Generation of three-dimensional retinal tissue with functional photoreceptors from human iPSCs. Nat Commun 2014; 5: 1-14
    CrossrefPubMedSearch in Google Scholar
  • 63 Achberger K, Haderspeck JC, Kleger A. et al. Stem cell-based retina models. Adv Drug Deliv Rev 2019; 140: 33-50
    CrossrefPubMedSearch in Google Scholar
  • 64 Akhtar T, Xie H, Khan MI. et al. Accelerated photoreceptor differentiation of hiPSC-derived retinal organoids by contact co-culture with retinal pigment epithelium. Stem Cell Res 2019; 39: 101491
    CrossrefPubMedSearch in Google Scholar
  • 65 Chichagova V, Georgiou M, Dorgau B. et al. Enhancing immune function of hiPSC-derived retinal organoids by incorporating microglial cells. Invest Ophthalmol Vis Sci 2020; 61: 3797
    PubMedSearch in Google Scholar
  • 66 Orlans HO, Edwards TL, De Silva SR. et al. Human Retinal Explant Culture for Ex Vivo Validation of AAV Gene Therapy. Methods Mol Biol 2018; 1715: 289-303
    CrossrefPubMedSearch in Google Scholar
  • 67 Murali A, Ramlogan-Steel CA, Andrzejewski S. et al. Retinal explant culture: A platform to investigate human neuro-retina. Clin Experiment Ophthalmol 2019; 47: 274-285
    CrossrefPubMedSearch in Google Scholar
  • 68 Asokan A, Schaffer DV, Samulski RJ. The AAV vector toolkit: poised at the clinical crossroads. Mol Ther 2012; 20: 699-708
    CrossrefPubMedSearch in Google Scholar